Clinical Trial Update: A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa [Phase 3]

View source ↗

Summary

Phase 3 study evaluating KB803 versus matched placebo in Dystrophic Epidermolysis Bullosa is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dominant Dystrophic Epidermolysis Bullosa
• Dystrophic Epidermolysis Bullosa
• Recessive Dystrophic Epidermolysis Bullosa

Drugs mentioned

• KB803

Snippet

Sponsor: Krystal Biotech, Inc. | Conditions: Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa | Phase 3 | Status: RECRUITING